Recombinant activated factor VII in cardiac surgery: A systematic review

被引：108

作者：

Warren, Oliver ^{[1
]}

Mandal, Kaushik ^{[1
]}

Hadjianastassiou, Vassilis ^{[1
]}

Knowlton, Lisa ^{[1
]}

Panesar, Sukhmeet ^{[1
]}

John, Kokotsakis ^{[1
]}

Darzi, Ara ^{[1
]}

Athanasiou, Thanos ^{[1
]}

机构：

[1] St Marys Hosp, Dept Biosurg & Surg Technol, Imperial Coll, Fac Med, London W2 1NY, England

来源：

ANNALS OF THORACIC SURGERY | 2007年 / 83卷 / 02期

关键词：

D O I：

10.1016/j.athoracsur.2006.10.033

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.

引用

页码：707 / 714

页数：8

共 85 条

[1]

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage [J].

Aggarwal A. ;

Malkovska V. ;

Catlett J.P. ;

Alcorn K. .

Thrombosis Journal, 2 (1)

[2]

Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery [J].

Al Douri, M ;

Shafi, T ;

Al Khudairi, D ;

Al Bokhari, E ;

Black, L ;

Akinwale, N ;

Musa, MO ;

Al Homaidhi, A ;

Al Fagih, M ;

Andreasen, RB .

BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 :S121-S127

[3]

The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients [J].

Aldouri, M .

PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2002, 32 :41-46

[4]

Recombinant activated factor VII: Treating postoperative hemorrhage in cardiac surgery [J].

Bishop, CV ;

Renwick, WEP ;

Hogan, C ;

Haeusler, M ;

Tuckfield, A ;

Tatoulis, J .

ANNALS OF THORACIC SURGERY, 2006, 81 (03) :875-879

[5]

Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials [J].

Boffard, KD ;

Riou, B ;

Warren, B ;

Choong, PIT ;

Rizoli, S ;

Rossaint, R ;

Axelsen, M ;

Kluger, Y .

JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2005, 59 (01) :8-16

[6]

THE CONTRIBUTIONS OF CA-2+, PHOSPHOLIPIDS AND TISSUE-FACTOR APOPROTEIN TO THE ACTIVATION OF HUMAN BLOOD-COAGULATION FACTOR-X BY ACTIVATED FACTOR-VII [J].

BOM, VJJ ;

BERTINA, RM .

BIOCHEMICAL JOURNAL, 1990, 265 (02) :327-336

[7]

Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII [J].

Bui, JD ;

Despotis, GD ;

Trulock, EP ;

Patterson, GA ;

Goodnough, LT .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 124 (04) :852-854

[8]

Active tissue factor in blood? [J].

Butenas, S ;

Mann, KG .

NATURE MEDICINE, 2004, 10 (11) :1155-1156

[9]

Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia [J].

Butenas, S ;

Brummel, KE ;

Paradis, SG ;

Mann, KG .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :123-129

[10]

Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass [J].

Chung, JH ;

Gikakis, N ;

Rao, AK ;

Drake, TA ;

Colman, RW ;

Edmunds, LH .

CIRCULATION, 1996, 93 (11) :2014-2018

← 1 2 3 4 5 6 7 8 9 →